“It’s not a new idea, it’s a very old idea,” said UC Irvine virologist Michael J. Buchmeier, who has studied the use of convalescent plasma for decades. In an age where genetically engineered antibodies are the new norm, convalescent plasma seems quaint. And for drug companies that require a profitable market to justify the design and production of a new vaccine it is a distinctly unprofitable approach, he said.
How the blood of coronavirus survivors may protect others from COVID-19
Los Angeles Times, March 19, 2020
March 19, 2020